Infection with mycobacterium tuberculosis remains an uncommon, but clinically important problem in the United States despite sustained public health efforts and the availability of effective antituberculous therapy for more than 50 years. An estimated 12,000 to 15,000 cases of active tuberculosis occur yearly in the United States and account for at least 600 deaths annually. Worldwide, tuberculosis is a major cause of morbidity and mortality, ranking among the top five most fatal infectious diseases.
The modern era of antituberculosis medications began in 1944 with the development of streptomycin for which Selman Waksman received the Nobel Prize. Subsequently, more potent agents with wider activity and better tolerability were developed including p-aminosalicylic acid (PAS) in 1949, isoniazid in 1952, pyrazinamide in 1954, ethambutol in 1962, rifampin in 1963 and cycloserine in 1964. The development of chemotherapy for tuberculosis is one of the great achievements of biomedical research in the 20th Century.
Importantly, however, the major first line antituberculosis medications have hepatotoxic potential, including clinically apparent acute liver disease as well as acute liver failure and death or need for emergency liver transplantation. Furthermore, combination therapy which is required for the therapy of active tuberculosis appears to be associated with a higher rate of hepatotoxicity than occurs with the individual agents by themselves.
The current recommended therapy of active tuberculosis is the combination of at least two potent antimycobacterial agents for 9 to 12 months, examples being isoniazid, rifampin, pyrazinamide and ethambutol (the two latter agents often given for the first 2 months). PAS (p-aminosalicylic acid) is now rarely used, partially because of its known hepatotoxicity. Ethambutol is used in instances of suspected or proven multidrug resistance. Other agents similar to rifampin which have activity against mycobacterium tuberculosis and several of the atypical mycobacteria include rifabutin and rifapentine. Second line agents, used in situations of toxicity of the first line agents or for multidrug resistance, include amikacin, azithromycin, capreomycin, cycloserine, ethionamide, levofloxacin, moxifloxacin, and streptomycin which in general have lower rates of hepatotoxicity.
Therapy is also recommended for latent tuberculosis or the finding of a positive protein derivative skin test, particularly in a high risk individual, after known exposure or with known skin test conversion. The primary regimen recommended for latent tuberculosis is a 9 month course of isoniazid. Alternative approaches include a 6 month course of isoniazid, a 4 month course of rifampin, and a 3 month course of isoniazid and rifapentine. The previous recommendation for using a 4 month course of rifampin and pyrazinamide is no longer recommended because of the potential for severe hepatotoxicity.
Regularly updated recommendations on the diagnosis, prevention and therapy of tuberculosis are available from the Centers for Disease Control and Prevention at: http://www.cdc.gov/tb/.
First line medications used in the therapy of tuberculosis include ethambutol, isoniazid, pyrazinamide, rifabutin, rifampin, and rifapentine. Second line medications include streptomycin, capreomycin, cycloserine, ethionamide, amikacin, levofloxacin, moxifloxacin, and para-aminosalicylic acid (PAS) (the latter is not discussed on this website). Finally, bedaquiline, the first new medication specifically for treatment of tuberculosis in more than forty years, was approved for use in the United States in 2012. Bedaquiline is currently limited in availability and is recommended only in therapy of multidrug resistant tuberculosis when an effective treatment regimen cannot otherwise be provided.